{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:24:24Z","timestamp":1741238664150,"version":"3.38.0"},"reference-count":43,"publisher":"JLE","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.nephro.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T07:17:33Z","timestamp":1554880653000},"page":"S115-S121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Traitement de l\u2019amylose AL"],"prefix":"10.1684","volume":"15","author":[{"given":"Arnaud","family":"Jaccard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Bridoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2019.03.002_bib0220","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346\u00a0patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0225","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2019.03.002_bib0230","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1515\/cclm-2016-1024","article-title":"Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays","volume":"55","author":"Palladini","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.nephro.2019.03.002_bib0235","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2019.03.002_bib0240","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease\u00a0using next-generation flow cytometry in patients with AL amyloidosis","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.nephro.2019.03.002_bib0245","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0250","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ajh.24772","article-title":"The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic","volume":"92","author":"Milani","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nephro.2019.03.002_bib0255","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2019.03.002_bib0260","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","article-title":"Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21\u00a0patients","volume":"101","author":"Moreau","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2019.03.002_bib0265","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","article-title":"Autologous stem cell transplantation for primary systemic amyloidosis","volume":"99","author":"Comenzo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0270","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.nephro.2019.03.002_bib0275","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2019.03.002_bib0280","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.12136","article-title":"Bortezomib in the treatment of AL amyloidosis: targeted therapy?","volume":"92","author":"Sitia","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.nephro.2019.03.002_bib0285","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0290","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.V128.22.646.646","article-title":"A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.nephro.2019.03.002_bib0295","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood.V126.23.190.190","article-title":"Accurate risk stratification identifies patients with AL amyloidosis benefiting most from upfront bortezomib combinations: a study of treatment outcomes in 984\u00a0patients [abstract]","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0300","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2019.03.002_bib0305","first-page":"21454","article-title":"A prospective phase II study of daratumumab in previously-treated systemic light- chain (al) amyloidosis","author":"Jaccard","year":"2018","journal-title":"Abstract: S851, EHA"},{"issue":"14","key":"10.1016\/j.nephro.2019.03.002_bib0310","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2010-02-268987","article-title":"Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)","volume":"117","author":"Bochtler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0315","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2017.183749","article-title":"Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone","volume":"103","author":"Leung","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.nephro.2019.03.002_bib0320","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0325","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2017.02.004","article-title":"Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis","volume":"76","author":"Le Bras","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nephro.2019.03.002_bib0330","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1182\/blood-2018-99-117695","article-title":"IgM associated light chain (AL) amyloidosis: delineating disease biology with clinical, genomic and bone marrow morphological features","volume":"132","author":"Sidana","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0335","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1182\/blood-2018-04-845396","article-title":"Treatment of AL amyloidosis with bendamustine: a study of 122\u00a0patients","volume":"132","author":"Milani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2018.06.017","article-title":"Autologous stem cell transplant for IgM-associated amyloid light chain amyloidosis","author":"Sidiqi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nephro.2019.03.002_bib0345","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0350","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clml.2017.06.004","article-title":"Primary amyloidosis with renal involvement: outcomes in 77\u00a0consecutive patients at a single center","volume":"17","author":"Wong","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.nephro.2019.03.002_bib0355","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2\u00a0trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0360","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2019.03.002_bib0365","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","article-title":"Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies","volume":"131","author":"Palladini","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0370","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1182\/blood-2018-99-114834","article-title":"Overview of the French practice: therapeutic strategies in patient's first relapse or refractory non IgM AL amyloidosis","volume":"132","author":"Villesuzanne","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0375","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II Study of NEOD001\u00a0in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2019.03.002_bib0380","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nephro.2019.03.002_bib0385","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/108497803322702824","article-title":"Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies","volume":"18","author":"Solomon","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nephro.2019.03.002_bib0390","first-page":"2016","article-title":"Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody","volume":"47","author":"Wall","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nephro.2019.03.002_bib0395","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13506129.2017.1292900","article-title":"Interim analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4\u00a0in patients with AL amyloidosis","volume":"24","author":"Edwards","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.nephro.2019.03.002_bib0400","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood-2018-99-118464","article-title":"Improvement in global longitudinal strain (GLS) correlates with NT-proBNP response in patients with cardiac amyloidosis treated on a phase 1b study of anti-amyloid Mab Cael-101","volume":"132","author":"Bhutani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0405","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline used as post-transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2019.03.002_bib0410","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer"},{"key":"10.1016\/j.nephro.2019.03.002_bib0415","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.nephro.2019.03.002_bib0420","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.nephro.2019.03.002_bib0425","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12185-016-2112-1","article-title":"Phase 2\u00a0trial of daily, oral epigallocatechinegallate in patients with light-chain amyloidosis","volume":"105","author":"Meshitsuka","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.nephro.2019.03.002_bib0215","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000\u00a0and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725519300410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725519300410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2019.03.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:21:55Z","timestamp":1741191715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725519300410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":43,"alternative-id":["S1769725519300410"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2019.03.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement de l\u2019amylose AL","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation.","name":"copyright","label":"Copyright"}]}}